Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
10 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-11-30
Study Completion Date
2021-10-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to assess the safety and efficacy of subcutaneous abatacept in 10 patients seven years of age and older with refractory JDM.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
NCT02466243
Dermatomyositis
TERMINATED
PHASE2
Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis
NCT07012057
Myositis
Dermatomyositis
WITHDRAWN
PHASE2
Safety and Efficacy of BAF312 in Dermatomyositis
NCT02029274
Active Dermatomyositis
TERMINATED
PHASE2
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375
Interstitial Lung Disease
Common Variable Immunodeficiency
RECRUITING
PHASE2
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
NCT02245841
Dermatomyositis
Juvenile Dermatomyositis
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
JDM is a chronic systemic autoimmune disease with a predominance of muscle and skin inflammation of unknown etiology and varying prognosis. Children with JDM unresponsive to corticosteroids or other immunosuppressive medications face poor clinical and functional outcome and suffer various sequelae of the disease. Abatacept is a fully human soluble recombinant protein consisting of the cytotoxic T cell Lymphocyte Antigen-4 (CTLA4) fused with Fc region of human IgG1 that has been modified to prevent complement fixation and antibody-dependent cellular cytotoxicity. Abatacept binds specifically to the CD80 (B7-1) and CD86 (B7-2) molecules, those expressed on antigen-presenting cells (APCs). Upon engagement of CTLA4 to CD80 or CD86, the resultant inhibition of signal transduction inhibits T cell activation.. The rationale for use of Abatacept in the therapy of JDM includes the expression of CTLA4, CD28, CD86, and CD40 on inflammatory cells of muscle biopsies of patients with DM, as well as CTLA4 and CD28 on muscle cells.
A patient's participation in this study will last approximately 24 weeks with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. Each injection will be given on an outpatient basis.
There will be a total of 6 study visits. All participants will visit the outpatient clinic at selected time points for muscle strength testing, a physical exam, disease activity measurements, blood and urine collection, and muscle MRI; they will also be asked to complete several questionnaires. During the study, participants will be monitored closely for improvement or worsening of their disease and for serious drug related side effects.
Eligibility Ages Eligible for Study: ≥ 7 years and older Genders Eligible for Study: Both Race/Ethnic Backgrounds Eligibility for Study: No restrictions
A patient's participation in this study will last approximately 24 weeks with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. Each injection will be given on an outpatient basis.
There will be a total of 6 study visits. All participants will visit the outpatient clinic at selected time points for muscle strength testing, a physical exam, disease activity measurements, blood and urine collection, and muscle MRI; they will also be asked to complete several questionnaires. During the study, participants will be monitored closely for improvement or worsening of their disease and for serious drug related side effects.
Eligibility Ages Eligible for Study: ≥ 7 years and older Genders Eligible for Study: Both Race/Ethnic Backgrounds Eligibility for Study: No restrictions
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Dermatomyositis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Label (One Arm)
A patient's participation in this study will last approximately 24 weeks ( screening visit and 5 intervention visits) with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. During intervention phase of the trial, muscle strength testing, physical exam, disease activity measurements, blood and urine collection, and muscle MRI will be performed. Participants will also be asked to complete several questionnaires. Participants will be also monitored closely for for serious drug related side effects.
Group Type
OTHER
Abatacept
Intervention Type
DRUG
Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Abatacept
Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Orencia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Adults with definite or probable JDM and pediatric patients 7 years of age and older with definite or probable JDM.
2. Body weight of at least 25 kg (or at least 55 lbs) and age ≥ 7 years of age.
3. Patients must reside within the United States or Canada.
4. Refractory myositis, as defined by the intolerance to or an inadequate response to corticosteroids plus an adequate regimen of at least one other immunosuppressive agent, including azathioprine, methotrexate, IVIG, mycophenolate mofetil, cyclophosphamide, tacrolimus or cyclosporine A, or a biologic therapy. The definition of intolerance is: side effects that require discontinuation of the medication or an underlying condition that precludes the further use of the medication.
5. At least moderately active disease as documented by:
* MD global VAS with a minimum value of 2.5 cm on a 10 cm scale AND
* At least 2 other abnormal core set measures listed below:
6. Therapy with prednisone or another glucocorticoid is required, unless there is documented intolerance in the medical record or a medical condition that contraindicates further use of prednisone. The prednisone dose must be stable for at least 4 weeks prior to the screening visit.
7. Background therapy with at least 1 non-corticosteroid immunosuppressive agent is required at a stable dose for at least 6 weeks prior to the screening visit unless there is documentation that the patient is intolerant, which is defined as side effects that require discontinuation of the medication(s) or an underlying condition that precludes the further use of the IS medication.
8. If an immunosuppressive agent was discontinued prior to the screening visit then there must be a:
* 4 week washout for prednisone or methotrexate
* 8 week washout for any other IS agent
* For discontinuation of biologic therapies, a washout of 5 terminal half lives
9. If on hydroxychloroquine or colchicine, the dose should be stable for 6 weeks prior to Visit 1.
10. If on statin or fibric acid derivative agents, the dose should be stable for 6 weeks prior to Visit 1.
11. Ability of patient or parent to complete self-report questionnaires.
12. Men and women of reproductive potential must agree to use a reliable method of birth control during the 24 week duration of the trial described in the reproductive risks section of this protocol (section 4.3). They must also agree to use a reliable method of birth control for 100 days after the last dose of study drug is administered.
13. Patients must agree to forgo immunization with a live vaccine during the course of the study or within 3 months after discontinuation.
14. Patients must have a letter from the referring rheumatologist or specialist supervising the care of the JDM, agreeing to the patient's participation in the study and to continuing to provide care for the patient, including emergency care during the trial.
Core Set Measures:
* An MMT-8 score that is no greater than 125/150
* Patient/Parent Global VAS with a minimum value of 2.0 cm on a 10cm scale
* CHAQ/HAQ disability index with a minimum value of 0.25
* Elevation of at least one of the muscle enzymes \[which includes creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\] at a minimum level of 1.3 x the upper limit of normal.
* Global extra-muscular disease activity score with a minimum value of 2.0 cm on a 10 cm VAS scale
2. Body weight of at least 25 kg (or at least 55 lbs) and age ≥ 7 years of age.
3. Patients must reside within the United States or Canada.
4. Refractory myositis, as defined by the intolerance to or an inadequate response to corticosteroids plus an adequate regimen of at least one other immunosuppressive agent, including azathioprine, methotrexate, IVIG, mycophenolate mofetil, cyclophosphamide, tacrolimus or cyclosporine A, or a biologic therapy. The definition of intolerance is: side effects that require discontinuation of the medication or an underlying condition that precludes the further use of the medication.
5. At least moderately active disease as documented by:
* MD global VAS with a minimum value of 2.5 cm on a 10 cm scale AND
* At least 2 other abnormal core set measures listed below:
6. Therapy with prednisone or another glucocorticoid is required, unless there is documented intolerance in the medical record or a medical condition that contraindicates further use of prednisone. The prednisone dose must be stable for at least 4 weeks prior to the screening visit.
7. Background therapy with at least 1 non-corticosteroid immunosuppressive agent is required at a stable dose for at least 6 weeks prior to the screening visit unless there is documentation that the patient is intolerant, which is defined as side effects that require discontinuation of the medication(s) or an underlying condition that precludes the further use of the IS medication.
8. If an immunosuppressive agent was discontinued prior to the screening visit then there must be a:
* 4 week washout for prednisone or methotrexate
* 8 week washout for any other IS agent
* For discontinuation of biologic therapies, a washout of 5 terminal half lives
9. If on hydroxychloroquine or colchicine, the dose should be stable for 6 weeks prior to Visit 1.
10. If on statin or fibric acid derivative agents, the dose should be stable for 6 weeks prior to Visit 1.
11. Ability of patient or parent to complete self-report questionnaires.
12. Men and women of reproductive potential must agree to use a reliable method of birth control during the 24 week duration of the trial described in the reproductive risks section of this protocol (section 4.3). They must also agree to use a reliable method of birth control for 100 days after the last dose of study drug is administered.
13. Patients must agree to forgo immunization with a live vaccine during the course of the study or within 3 months after discontinuation.
14. Patients must have a letter from the referring rheumatologist or specialist supervising the care of the JDM, agreeing to the patient's participation in the study and to continuing to provide care for the patient, including emergency care during the trial.
Core Set Measures:
* An MMT-8 score that is no greater than 125/150
* Patient/Parent Global VAS with a minimum value of 2.0 cm on a 10cm scale
* CHAQ/HAQ disability index with a minimum value of 0.25
* Elevation of at least one of the muscle enzymes \[which includes creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\] at a minimum level of 1.3 x the upper limit of normal.
* Global extra-muscular disease activity score with a minimum value of 2.0 cm on a 10 cm VAS scale
Exclusion Criteria
1. Drug-induced myositis (myositis in patients taking medications known to induce myositis-like syndromes, including, but not limited to, statin agents, fibric acid derivatives, and colchicine).
2. Juvenile polymyositis; inclusion body myositis; cancer-associated myositis, defined as the diagnosis of myositis within 2 years of the diagnosis of cancer except basal or squamous cell skin cancer or carcinoma in situ of the cervix if at least 5 years since excision
3. Myositis in overlap with another connective tissue disease (CTD) that precludes the accurate assessment of a treatment response (for example, difficulty in assessing muscle strength in a scleroderma patient with associated myositis)
4. History of receiving a live vaccine 4 weeks prior to initiation of study treatment
5. Joint disease, severe calcinosis, or other musculoskeletal condition, which precludes the ability to quantitate muscle strength.
6. Wheelchair bound patients.
7. Known hypersensitivity to abatacept or prior receipt of abatacept
8. Concomitant illness that would prevent adequate patient assessment or in the investigators opinion pose an added risk for study participants:
9. Recurrent or chronic infections, including HIV, tuberculosis, hepatitis B and C, or TB infection, including contact with a household contact with active tuberculosis (TB) and who did not receive appropriate and documented prophylaxis for TB. (a documented negative Hepatitis B surface antigen and Hepatitis C antibody completed at the screening visit or within 6 weeks prior to screening visit is required)
10. Have had symptomatic herpes zoster or herpes simplex infection (not including simple oral HSV lesions) within 12 weeks prior to entry or during screening period
11. Have a history of disseminated/complicated herpes zoster (for example, multi-dermatomal involvement, ophthalmic zoster, central nervous system (CNS) involvement, post-herpetic neuralgia)
12. Known liver disease (i.e. cirrhosis or other conditions compromising the synthetic function of the liver)
13. Disorders that would preclude accurate assessment of neuromuscular function
14. Cardiomyopathy or arrhythmias that in the investigators opinion poses an additional risk for study participants
15. New York Heart Association Classification III or IV for congestive heart failure
16. Psychiatric illness that precludes compliance or neuromuscular assessment
17. Serum creatinine \> 2.0mg/dl
18. Pregnant females or nursing mothers
19. Life threatening illness that would interfere with the patient's ability to complete the study.
20. Known or suspected history of drug or alcohol abuse within the past 6 months as determined by the medical record or patient interview
21. Anticipated poor compliance
22. Participation in another clinical experimental therapeutic study within 30 days of screening visit.
23. Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study.
24. Low total WBC \<2.000, platelets \< 100,000/mm3; hemoglobin \<10 gm/dl
25. History of recurrent infection including active skin infections with calcinosis
26. Subjects with a history of cancer in the last 5 years
27. Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the day 1 dose of study drug, including waiting until CD19 returns to a detectable level and IgG level is within normal limits (normal serum levels of IgG per reference lab: 7-9 years ≥572 mg/dl, 10-11 yrs ≥698 mg/dl, 12-13 yrs ≥759 mg/dl, 14-15 yrs ≥716 mg/dl,16-19 yrs ≥549 mg/dl, \>19 yrs ≥700 mg/dl) for those patients who have received rituximab
28. Concomitant treatment with anti-TNF therapies, rituximab or anakinra or other biologic therapies.
29. Initiation of colchicine and hydroxychloroquine as new drugs during study participation is not allowed.
30. Initiation of statins or fibric acid derivatives during study participation is not allowed.
31. Initiation of an exercise program within 4 weeks of the screening visit. Only a stretching program may be initiated during the study (See section 5.4 Other Restrictions)
32. Prisoners or subjects who are involuntarily incarcerated.
33. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
2. Juvenile polymyositis; inclusion body myositis; cancer-associated myositis, defined as the diagnosis of myositis within 2 years of the diagnosis of cancer except basal or squamous cell skin cancer or carcinoma in situ of the cervix if at least 5 years since excision
3. Myositis in overlap with another connective tissue disease (CTD) that precludes the accurate assessment of a treatment response (for example, difficulty in assessing muscle strength in a scleroderma patient with associated myositis)
4. History of receiving a live vaccine 4 weeks prior to initiation of study treatment
5. Joint disease, severe calcinosis, or other musculoskeletal condition, which precludes the ability to quantitate muscle strength.
6. Wheelchair bound patients.
7. Known hypersensitivity to abatacept or prior receipt of abatacept
8. Concomitant illness that would prevent adequate patient assessment or in the investigators opinion pose an added risk for study participants:
9. Recurrent or chronic infections, including HIV, tuberculosis, hepatitis B and C, or TB infection, including contact with a household contact with active tuberculosis (TB) and who did not receive appropriate and documented prophylaxis for TB. (a documented negative Hepatitis B surface antigen and Hepatitis C antibody completed at the screening visit or within 6 weeks prior to screening visit is required)
10. Have had symptomatic herpes zoster or herpes simplex infection (not including simple oral HSV lesions) within 12 weeks prior to entry or during screening period
11. Have a history of disseminated/complicated herpes zoster (for example, multi-dermatomal involvement, ophthalmic zoster, central nervous system (CNS) involvement, post-herpetic neuralgia)
12. Known liver disease (i.e. cirrhosis or other conditions compromising the synthetic function of the liver)
13. Disorders that would preclude accurate assessment of neuromuscular function
14. Cardiomyopathy or arrhythmias that in the investigators opinion poses an additional risk for study participants
15. New York Heart Association Classification III or IV for congestive heart failure
16. Psychiatric illness that precludes compliance or neuromuscular assessment
17. Serum creatinine \> 2.0mg/dl
18. Pregnant females or nursing mothers
19. Life threatening illness that would interfere with the patient's ability to complete the study.
20. Known or suspected history of drug or alcohol abuse within the past 6 months as determined by the medical record or patient interview
21. Anticipated poor compliance
22. Participation in another clinical experimental therapeutic study within 30 days of screening visit.
23. Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study.
24. Low total WBC \<2.000, platelets \< 100,000/mm3; hemoglobin \<10 gm/dl
25. History of recurrent infection including active skin infections with calcinosis
26. Subjects with a history of cancer in the last 5 years
27. Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the day 1 dose of study drug, including waiting until CD19 returns to a detectable level and IgG level is within normal limits (normal serum levels of IgG per reference lab: 7-9 years ≥572 mg/dl, 10-11 yrs ≥698 mg/dl, 12-13 yrs ≥759 mg/dl, 14-15 yrs ≥716 mg/dl,16-19 yrs ≥549 mg/dl, \>19 yrs ≥700 mg/dl) for those patients who have received rituximab
28. Concomitant treatment with anti-TNF therapies, rituximab or anakinra or other biologic therapies.
29. Initiation of colchicine and hydroxychloroquine as new drugs during study participation is not allowed.
30. Initiation of statins or fibric acid derivatives during study participation is not allowed.
31. Initiation of an exercise program within 4 weeks of the screening visit. Only a stretching program may be initiated during the study (See section 5.4 Other Restrictions)
32. Prisoners or subjects who are involuntarily incarcerated.
33. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
Minimum Eligible Age
7 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
George Washington University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rodolfo Curiel
Dr. Rodolfo V. Curiel, MD, Associate Professor of Medicine, Division of Rheumatology; Director, Myositis Center
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodolfo V Curiel, MD
Role: PRINCIPAL_INVESTIGATOR
The George Washington University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2300 M Street, 9th floor. Medical Faculty Associates, The George Washington University.
Washington D.C., District of Columbia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008 Jun 28;371(9631):2201-12. doi: 10.1016/S0140-6736(08)60955-1.
Reference Type
BACKGROUND
Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol. 2009 Oct;23(5):665-78. doi: 10.1016/j.berh.2009.07.007.
Reference Type
BACKGROUND
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754.
Reference Type
BACKGROUND
Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, Tresser N, Abati A, Fetsch P, Plotz PH. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol. 1999 Aug;92(2):161-9. doi: 10.1006/clim.1999.4743.
Reference Type
BACKGROUND
Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol. 1999 Aug;155(2):453-60. doi: 10.1016/s0002-9440(10)65141-3.
Reference Type
BACKGROUND
Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol. 1998 Dec 1;161(11):5943-51.
Reference Type
BACKGROUND
Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993 Nov 4;366(6450):76-9. doi: 10.1038/366076a0.
Reference Type
BACKGROUND
Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013 Jun;52(6):986-97. doi: 10.1093/rheumatology/ket018. Epub 2013 Mar 5.
Reference Type
BACKGROUND
Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012 Mar;160(3):520-2. doi: 10.1016/j.jpeds.2011.11.057. Epub 2012 Jan 13.
Reference Type
BACKGROUND
Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine. 2011 Jul;78(4):431-2. doi: 10.1016/j.jbspin.2011.03.022. Epub 2011 May 7. No abstract available.
Reference Type
BACKGROUND
Maeshima K, Kiyonaga Y, Imada C, Iwakura M, Hamasaki H, Haranaka M, Ishii K. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford). 2014 Feb;53(2):379-80. doi: 10.1093/rheumatology/ket251. Epub 2013 Aug 6. No abstract available.
Reference Type
BACKGROUND
Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Alcala JO, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace C, Alessio M, Quartier P, Cortis E, Eberhard A, Simonini G, Lemelle I, Chalom EC, Sigal LH, Block A, Covucci A, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1542-51. doi: 10.1002/acr.20283. Epub 2010 Jul 1.
Reference Type
BACKGROUND
Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW; International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004 Jul;50(7):2281-90. doi: 10.1002/art.20349.
Reference Type
BACKGROUND
Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flato B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Gare BA, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1533-41. doi: 10.1002/acr.20280. Epub 2010 Jun 25.
Reference Type
BACKGROUND
Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013 May;72(5):686-93. doi: 10.1136/annrheumdis-2012-201483. Epub 2012 Jun 26.
Reference Type
BACKGROUND
Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, Haji-Momenian S, Sheets R, Kim H, Jones OY, Rider LG; Abatacept in Dermatomyositis (AID) Trial Investigators. Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy. Arthritis Rheumatol. 2023 Jul;75(7):1229-1237. doi: 10.1002/art.42450. Epub 2023 Jun 7.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB 111418
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
NCT00005571
COMPLETED
PHASE2
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
NCT01954979
COMPLETED
PHASE1
Study of Tofacitinib in Refractory Dermatomyositis
NCT03002649
COMPLETED
PHASE1
Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
NCT01148810
TERMINATED
PHASE2
Study of IFN-K in Dermatomyositis
NCT02980198
WITHDRAWN
PHASE2
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
NCT01803321
COMPLETED
PHASE1
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
NCT03894956
COMPLETED
Safety and Efficacy of Abatacept in IgG4-Related Disease
NCT03669861
COMPLETED
PHASE2
Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis
NCT00033891
COMPLETED
PHASE2
Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome
NCT03899103
COMPLETED
PHASE3
Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
NCT01571895
TERMINATED
PHASE2
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
NCT05192200
COMPLETED
PHASE2
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
NCT00886795
COMPLETED
PHASE1/PHASE2
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325
COMPLETED
PHASE1/PHASE2
Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
NCT03529955
COMPLETED
PHASE2
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
NCT03733067
WITHDRAWN
PHASE1/PHASE2
Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
NCT07202598
RECRUITING
PHASE2
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
NCT06012448
COMPLETED
PHASE4
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
NCT02421172
COMPLETED
PHASE2
Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195
NCT02881853
COMPLETED
PHASE1
Infliximab to Treat Children With Juvenile Rheumatoid Arthritis
NCT00029042
TERMINATED
PHASE2
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575
RECRUITING
PHASE1
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
NCT06987539
RECRUITING
PHASE2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07124078
RECRUITING
PHASE2
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
NCT00358449
COMPLETED
PHASE2